13F-HR filed by Summit Rock Advisors, LP
Summit Rock Advisors, LP filed this 13F-HR for the quarter ended 2021-12-31, filed 2022-02-14, with 8 holding rows worth $167,420,000.
- Accession
- 0001172661-22-000818
- Filer
- CIK 1540951
- Filed
- 2022-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2021
A holdings report, 8 entries on the cover page, a total value of $167,420,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $167,420,000 with VALUE read as thousands by filing date, 13F file number 028-14655. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| Vanguard Value ETF | 922908744 | SHS | 413,962 | $60,898,000 | thousands by filing date | |
| iShares Core S&P U.S. Value ETF | 464287663 | SHS | 740,195 | $56,506,000 | thousands by filing date | |
| ISHARES TR | 464287630 | RUS 2000 VAL ETF | 283,472 | $47,071,000 | thousands by filing date | |
| CLOVER HEALTH INVESTMENTS CO | 18914F103 | COMMON STOCK | 210,639 | $784,000 | thousands by filing date | |
| PHATHOM PHARMACEUTICALS INC | 71722W107 | COMMON STOCK | 34,100 | $671,000 | thousands by filing date | |
| Day One Biopharmaceuticals Inc | 23954D109 | Common Stock | 33,125 | $558,000 | thousands by filing date | |
| MONDAY COM LTD SHS | M7S64H106 | Stock | 1,676 | $517,000 | thousands by filing date | |
| DYNE THERAPEUTICS INC COM | 26818M108 | Stock | 34,887 | $415,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001172661-22-000818 | this filing | 2022-02-14 | acceptance time not in the bulk data set |